Clinical Endocrinology and Diabetes at a Glance E-Book

Aled Rees

• Herausgeber: John Wiley & Sons
• Kategorie: Fachliteratur
• Serie: At a Glance
• Sprache: Englisch
• Veröffentlichungsjahr: 2017

Seitenzahl: 242

Beschreibung

Clinical Endocrinology and Diabetes at a Glance The market-leading at a Glance series is popular among healthcare students, and newly qualified practitioners for its concise and simple approach and excellent illustrations. Each bite-sized chapter is covered in a double-page spread with clear, easy-to-follow diagrams, supported by succinct explanatory text. Covering a wide range of topics, books in the at a Glance series are ideal as introductory texts for teaching, learning and revision, and are useful throughout university and beyond. Everything you need to know about Clinical Endocrinology and Diabetes... at a Glance! Recognizing a need to promote and enhance teaching of clinical endocrinology and diabetes in UK medical schools, the Society for Endocrinology, in collaboration with Diabetes UK and the Association of British Clinical Diabetologists, created a national curriculum that sets out the minimum recommended standards for undergraduate medical education. Clinical Endocrinology and Diabetes at a Glance corresponds to the curriculum and covers all important areas of diabetes and endocrinology in a clinically relevant and concise manner, with complementary figures to ensure principles are explained clearly. It highlights key practical skills for undergraduates in line with the GMC recommendations that medical graduates should be well prepared for in their Foundation posts. There is also emphasis on the importance of multidisciplinary teams in the management of endocrine diseases and diabetes. These include sections on structured education programmes, psychosocial aspects, and patient self-management and monitoring. Clinical Endocrinology and Diabetes at a Glance will serve as a valuable resource for medical students and junior doctors treating patients with these conditions

Leseprobe

This title is also available as an e-book.

For more details, please see

www.wiley.com/buy/9781119128717

or scan this QR code:

Clinical Endocrinology and Diabetes at a Glance

Aled Rees

Consultant Endocrinologist School of Medicine Cardiff University Cardiff, UK

Miles Levy

Consultant Endocrinologist University Hospitals of Leicester Leicester, UK

Andrew Lansdown

Consultant Endocrinologist University Hospital of Wales Cardiff, UK

This edition first published 2017 © 2017 by John Wiley & Sons, Ltd

Registered office: John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK 111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/wiley-blackwell

The right of the authors to be identified as the authors of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by health science practitioners for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

Names: Rees, Aled, author. | Levy, Miles, 1971- author. | Lansdown, Andrew,  1980- author.

Title: Clinical endocrinology and diabetes at a glance / Aled Rees, Miles Levy,  Andrew Lansdown.

Other titles: At a glance series (Oxford, England)

Description: Chichester, West Sussex, UK ; Hoboken, NJ : John Wiley & Sons Inc.,  2017. | Series: At a glance series | Includes index.

Identifiers: LCCN 2016039440| ISBN 9781119128717 (pbk.) | ISBN 9781119128724  (Adobe PDF) | ISBN 9781119128731 (epub)

Subjects: | MESH: Endocrine System Diseases—diagnosis | Diabetes  Mellitus—diagnosis | Handbooks

Classification: LCC RC648 | NLM WK 39 | DDC 616.4/8—dc23 LC record available at https://lccn.loc.gov/2016039440

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Cover image: © SHUBHANGI GANESHRAO KENE/Gettyimages

CONTENTS

Preface

Part 1: Introduction

1: Introduction to endocrinology

Synthesis, release and transport

Mechanisms of hormone action

Control and feedback

Patterns of hormone secretion

Measurement of hormones

Dynamic endocrine tests

Part 2: Disorders of the hypothalamic–pituitary axis

2: The hypothalamic–pituitary axis and its assessment

Physiology

Assessment of the pituitary gland

Imaging

3: Acromegaly

Clinical features

Investigation

Management

4: Cushing’s syndrome

Clinical features

Investigation

Differential diagnosis

Management

Follow-up and monitoring

5: Hypopituitarism and non-functioning pituitary adenomas

Non-functioning pituitary adenomas

Hypopituitarism

6: Prolactinoma and hyperprolactinaemia

Hyperprolactinaemia

Prolactinoma

Pituitary incidentaloma

Part 3: Disorders of thirst and fluid balance

7: Hypernatraemia and diabetes insipidus

Posterior pituitary function and sodium homeostasis

Hypernatraemia

Diabetes insipidus

Acute severe hypernatraemia

8: Hyponatraemia and SIADH

Hyponatraemia

Syndrome of inappropriate ADH

Acute severe hyponatraemia

Part 4: Thyroid disorders

9: Thyroid function

Anatomy

Physiology

Actions of thyroid hormones

Interpreting thyroid function tests

Primary and secondary hypothyroidism

Hyperthyroidism

Factors affecting thyroid results

10: Hyperthyroidism: clinical presentation and investigation

Causes

Clinical presentation

Investigation

11: Hyperthyroidism: management and ophthalmopathy

Medical treatment

Definitive treatments

Thyroid ophthalmopathy

12: Hyperthyroidism: special circumstances

Hyperthyroidism and pregnancy

Subclinical hyperthyroidism

Elevated fT4 with unsuppressed TSH

Assay interference

TSHoma and thyroid hormone resistance

13: Hypothyroidism

Causes

Clinical features

Investigations

Treatment

Subclinical hypothyroidism

Hypothyroidism and pregnancy

Polyglandular autoimmune disease

14: Goitre, thyroid nodules and cancer

Goitre

Multinodular goitre

Solitary thyroid nodule

Thyroid cancer

Management of differentiated thyroid cancer

Part 5: Disorders of calcium homeostasis

15: Physiology of calcium, PTH and vitamin D metabolism

Parathyroid hormone

Vitamin D

Vitamin D deficiency

16: Hypercalcaemia

Hypercalcaemia with suppressed PTH

Hypercalcaemia with non-suppressed PTH

Acute severe hypercalcaemia

17: Hypocalcaemia

Causes

Clinical features

Investigation

Treatment

Pseudo-hypoparathyroidism

18: Osteoporosis

Causes

Clinical features

Investigation

Assessing fracture risk

Treatment

Part 6: Disorders of the adrenal gland

19: Steroid physiology and biochemical assessment

Steroid synthesis

Glucocorticoids

Adrenal androgens

Mineralocorticoids

Biochemical assessment of the adrenal axis

20: Adrenal insufficiency

Primary adrenal insufficiency

Secondary adrenal insufficiency

Steroid-induced hypoadrenalism

21: Adrenocortical tumours

Adrenal Cushing’s syndrome

Primary hyperaldosteronism

Adrenal incidentalomas

22: Disorders of the adrenal medulla

Phaeochromocytoma and paraganglioma

Part 7: Disorders of the reproductive system

23: Physiology of the reproductive system

Physiology of female reproduction

Physiology of male reproduction

24: Growth, puberty and sexual differentiation

Normal growth

Normal puberty

Short stature

Precocious puberty

Delayed puberty

Sexual differentiation

Transition of young people into the adult service

25: Menstrual disturbance

Definition

Causes

Assessment

Treatment

Premature ovarian failure

Turner’s syndrome

26: Hyperandrogenism

Hirsutism

Polycystic ovary syndrome

Congenital adrenal hyperplasia

27: Menopause and HRT

Definition

Clinical presentation

Assessment

Treatment

Long-term risks and benefits

Pre-menopausal oestrogen replacement

28: Male hypogonadism

Definition

Primary hypogonadism

Secondary hypogonadism

Late onset hypogonadism

Assessment

Treatment

29: Gynaecomastia

Definition

Causes

Assessment

Treatment

30: Infertility

Definition and aetiology

Evaluation of the infertile couple

Investigations

Management

Part 8: Neuroendocrine tumours

31: Neuroendocrine tumours

Definition

Aetiology

Symptoms and signs

Diagnosis

32: Neuroendocrine tumours: management

Treatment

Carcinoid heart disease

Prognosis

33: Inherited endocrine tumour syndromes

Multiple endocrine neoplasia type 1

Multiple endocrine neoplasia type 2

Carney complex

McCune–Albright syndrome

34: Spontaneous hypoglycaemia

Fasting hypoglycaemia

Postprandial hypoglycaemia

Assessment

Management

Part 9: Endocrine emergencies

35: Adrenal crisis

Clinical presentation

Management

36: Pituitary apoplexy

Clinical presentation

Management

37: Myxoedema coma

Clinical presentation

Management

38: Thyroid storm

Clinical presentation

Investigations

Management

39: Acute hyponatraemia

Clinical presentation

Management

40: Severe hypercalcaemia

Clinical presentation

Management

41: Acute hypocalcaemia

Clinical presentation

Management

Part 10: Diabetes mellitus

42: Overview

History

Landmark studies

Advances in care

Diabetes support organisations

Awareness

43: Diagnosis and monitoring

Diagnosis of diabetes

Oral glucose tolerance test

Impaired fasting glycaemia and impaired glucose tolerance

Screening

Monitoring diabetes

44: Classification

Type 1 diabetes

Type 2 diabetes

Maturity-onset diabetes of the young

Other genetic defects in β-cell function

Genetic defects in insulin action

Pancreatic diseases

Endocrine disorders

Drugs

Gestational diabetes

Other associations with diabetes

45: Type 1 diabetes: aetiology and clinical presentation

Aetiology

Pathophysiology

Clinical presentation

46: Type 1 diabetes: insulin and other therapies

Lifestyle

Insulin

Continuous subcutaneous insulin infusion

Pancreatic transplantation

The artificial pancreas

Immunotherapy

47: Type 2 diabetes: aetiology and clinical presentation

Aetiology

Pathophysiology

Clinical presentation

48: Type 2 diabetes: treatment

Diet and exercise

Metformin

Sulphonylureas

Meglitinides

Acarbose

Glitazones

DPP-4 inhibitors

GLP-1 receptor agonists

SGLT-2 inhibitors

Insulin

49: Macrovascular complications

Epidemiology

Aetiology

Clinical presentation

Management

50: Microvascular complications

Background

Aetiology

Neuropathy

Nephropathy

Retinopathy

51: Diabetic foot disease

Epidemiology

Aetiology

Clinical presentation

Management

Prognosis

52: Diabetic ketoacidosis

Definition and epidemiology

Aetiology

Symptoms and signs

Investigations

Management

Prognosis

53: Hyperglycaemic hyperosmolar state

Definition and epidemiology

Aetiology

Symptoms and signs

Investigations

Management

Prognosis

54: Hypoglycaemia

Definition and epidemiology

Aetiology

Symptoms and signs

Investigations

Management

Prognosis

55: Peri-operative management

Pathophysiological factors

Pre-operative management

Intra-operative management

Postoperative management

56: Management of acute illness

Aims of management

Monitoring

Drug management

Calorie and fluid intake

Special groups for consideration

57: Insulin infusions

Variable-rate intravenous insulin infusion

Fixed-rate intravenous insulin infusion

58: Pregnancy and diabetes

Epidemiology

Pathophysiology

Complications

Pre-conception care

Screening for GDM

Antenatal care

Peri- and postnatal care

Postnatal diabetes screening

59: Genetics of diabetes

Type 1 diabetes

Type 2 diabetes

Maturity onset diabetes of the young

Mitochondrial diabetes

Neonatal diabetes

Monogenic disorders of insulin resistance

60: The multidisciplinary team

Diagnosis and surveillance

Life stages

Disease stages

Setting

61: Lipid disorders

Primary hyperlipidaemias

Secondary hyperlipidaemias

62: Appetite and weight

Central regulation

Gut regulation

Long-term regulation

Clinical assessment

63: Obesity and anorexia

Obesity

Anorexia

Index

EULA

List of Tables

Chapter 55

Table 55.1

Table 55.2

Chapter 56

Table 56.1

Guide

Cover

Table of Contents

Preface

Pages

vii

1

2

3

5

6

7

8

9

10

11

12

13

14

15

17

18

19

20

21

23

24

25

26

27

28

29

30

31

32

33

34

35

37

38

39

40

41

42

43

44

45

47

48

49

50

51

52

53

54

55

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

75

76

77

78

79

80

81

82

83

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

101

102

103

104

105

106

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

Preface

This concise and informative textbook is aimed primarily at medical undergraduates commencing their clinical rotations, and is the first of its kind to be aligned against a nationally endorsed curriculum (developed by the Society for Endocrinology, Diabetes UK and the Association of British Clinical Diabetologists). Feedback from our students has informed our approach to this book, which seeks to progress the reader from a fundamental understanding of the physiological mechanisms underpinning endocrine regulation through to disease processes which disturb this homeostatic balance. In addition to the core material on common endocrine and diabetes presentations, there is an emphasis on key practical skills and provision of clear guidance on peri-operative management, emergency presentations and acute illness. We therefore anticipate that Clinical Endocrinology and Diabetes at a Glance will form a helpful and accessible resource for junior doctors involved in the management of patients with diabetes and endocrine disorders. As with other books in the series there is a major emphasis on the use of clear illustrations and tables to complement the text and consolidate learning.

Parts 1 to 9 cover the regulation and assessment of the endocrine system, pituitary disorders, fluid and electrolyte balance, thyroid disease, metabolic bone disorders, adrenal disease, disorders of the reproductive system, neuroendocrine tumours and endocrine emergencies. Part 10 provides a comprehensive overview of all aspects of diabetes, lipid and weight disorders.

Finally, no textbook makes it to publication without the hard work of a number of contributors. We are particularly grateful to Karen Moore for her diligence in keeping our writing endeavours on track, and to Jan East and Kathy Syplywczak for their help in taking us through the production process.

We welcome any feedback, and hope you enjoy reading the book as much as we have enjoyed writing it.

Aled ReesMiles LevyAndrew LansdownFebruary 2017

Part 1Introduction

Chapter

1

Introduction to endocrinology

1Introduction to endocrinology

The endocrine system consists of glands, which secrete hormones that circulate and act at distant sites in the body. The key endocrine glands are the pituitary, thyroid, parathyroids, adrenals, pancreas and gonads. Endocrine disease can lead to hypo- or hypersecretion of hormones. Endocrine diseases include tumours, which are commonly benign, autoimmune diseases, enzyme defects and hormone receptor abnormalities.

Synthesis, release and transport

The chemical structure of hormones includes steroids, polypeptides, glycoproteins and amines (Figure 1.1). Hormones are secreted by the hypothalamus at low concentration, acting locally on the anterior pituitary, which in turn secretes trophic hormones to the relevant target gland. Hormones are secreted directly into the circulation either in their final form or as a larger precursor molecule, such as proopiomelanocortin (POMC), which is cleaved to adrenocorticotrophic hormone (ACTH), melanocyte stimulating hormone (MSH) and other smaller peptides. Many hormones are transported in the circulation by binding proteins, but only the free hormone acts on the receptor. Examples of binding proteins are sex hormone binding globulin (SHBG), which binds testosterone, and cortisol binding globulin (CBG), which binds cortisol.

Mechanisms of hormone action

Cell-surface receptors

Peptide hormones act on cell-surface receptors and exert their effect by activating cyclic adenosine monophosphate (cAMP). Most peptide hormones act via G-protein coupled receptors, most commonly a 7-trans-membrane (7TM) receptor (Figure 1.1). Examples of peptide hormones are growth hormone (GH), thyroid stimulating hormone (TSH), prolactin and ACTH.

Intranuclear receptors

Lipid-soluble hormones such as steroids and thyroid hormones pass through the cell membrane and act on intranuclear receptors, causing altered gene transcription (Figure 1.1).

Control and feedback

Hormones are usually controlled by a negative feedback mechanism (Figure 1.1). Using the thyroid axis as an example, the hypothalamus secretes its thyrotrophin releasing hormone (TRH), which travels down the portal tract to act on the anterior pituitary. The pituitary releases its trophic hormone (TSH) into the circulation, which acts on the target gland, stimulating the production of the relevant hormone (thyroxine). If the target gland hormone is too low, there is loss of negative feedback and a compensatory increase in the pituitary hormone (low T4, high TSH). If the target gland hormone is too high, there is increased negative feedback and suppression of the pituitary hormone (high T4, low TSH). All pituitary hormones are under predominantly stimulatory control by the hypothalamus apart from prolactin, which is under tonic inhibition by dopamine.

Patterns of hormone secretion

Some hormones are produced in a stable pattern with little circadian rhythmicity, for example thyroxine and prolactin. Other hormones have a significant diurnal variation. For example, cortisol is highest in the morning and lowest at midnight. Minor circadian rhythms can be seen with certain hormones such as testosterone, which is slightly higher in the morning than the afternoon. It is important to measure hormones at the appropriate time of day when assessing for deficiency or excess. Female hormones have a monthly cyclical variation and must be interpreted according to the time of the menstrual cycle.

Measurement of hormones

Hormones are usually measured by immunoassay, which uses specific labelled antibodies that give a signal according to the concentration of hormone. Interfering antibodies can affect blood results, so some results are not reflective of the true concentration of hormone. Assay interference should be suspected in any blood result that does match the clinical picture. Mass spectrometry is a newer technique that provides a more specific measure, and is increasingly being adopted in endocrine laboratories.

Dynamic endocrine tests

When basal investigations are difficult to interpret because of diurnal variation or equivocal results, 24-hour urine collection or dynamic blood tests can be helpful. If hormone deficiency is suspected, a stimulation test is used. This involves administration of a hormone that stimulates the target gland to increase its hormone secretion. Examples are the Synacthen test (to stimulate cortisol in suspected primary adrenal failure) and the insulin tolerance test (to stimulate GH and ACTH in suspected hypopituitarism). If hormone excess is suspected, a suppression test is used. Examples are the dexamethasone suppression test (to suppress cortisol in suspected Cushing’s syndrome) and the oral glucose tolerance test (to suppress GH in suspected acromegaly).

Part 2Disorders of the hypothalamic–pituitary axis

Chapters

2

The hypothalamic–pituitary axis and its assessment

3

Acromegaly

4

Cushing’s syndrome

5

Hypopituitarism and non-functioning pituitary adenomas

6

Prolactinoma and hyperprolactinaemia

2The hypothalamic–pituitary axis and its assessment

The pituitary gland is the ‘conductor of the endocrine orchestra’, controlling all peripheral glands via trophic hormones. It is approximately the size of a pea and sits in the pituitary fossa at the base of the brain (Figure 2.1). The anterior pituitary is derived embryologically from Rathke’s pouch, derived from primitive gut tissue. The posterior pituitary is derived from a down-growth of primitive brain tissue. The optic chiasm lies superior to the pituitary gland. Lateral is the cavernous sinus, which contains cranial nerves III, IV and Va and the internal carotid artery (Figure 2.1).

Physiology

Hypothalamic releasing and inhibiting factors are transported along the hypophyseal portal tract to the anterior pituitary. There are five pituitary axes: GH, ACTH, gonadotrophins (FSH and LH), TSH and prolactin (Table 2.1).

Growth hormone

GH is secreted in a pulsatile manner with peak pulses during REM sleep. GH acts on the liver to produce IGF-1, which is used as a marker of GH activity. GH exerts its action both by direct effects of GH and via IGF-1. GH causes musculoskeletal growth in children and has an important role in adults. Growth hormone releasing hormone (GHRH) stimulates GH, while somatostatin inhibits it.

ACTH

ACTH has a circadian rhythm, with peak pulses early in the morning and lowest activity at midnight. ACTH stimulates cortisol release, and is itself stimulated by corticotrophin releasing hormone (CRH). Cortisol is the only hormone that inhibits ACTH.

Gonadotrophins (FSH and LH)

FSH leads to ovarian follicle development in women and spermatogenesis in men. In women, LH causes mid-cycle ovulation during the LH surge and formation of the corpus luteum. In men, LH drives testosterone secretion from testicular Leydig cells. Gonadotrophin releasing hormone (GnRH) stimulates LH and FSH release. Testosterone and oestrogen inhibit LH and FSH, while prolactin also has a direct inhibitory effect.

TSH

TSH drives thyroxine release via stimulation of TSH receptors in the thyroid gland. TRH stimulates TSH secretion and is a weak stimulator of prolactin secretion. Thyroxine directly inhibits TSH.

Prolactin

Prolactin causes lactation and inhibits LH and FSH. It is under predominantly negative control by dopamine and weak stimulatory control by TRH. Anything that inhibits dopamine leads to an elevation in prolactin level.

Assessment of the pituitary gland

Pituitary tumours develop as a result of compression of local structures and/or the effects of endocrine hypo- or hypersecretion. Compression of the optic chiasm classically leads to a bi-temporal hemianopia. Assessment of visual fields with a red pin is a mandatory part of the clinical examination of patients with pituitary tumours. Automated visual field assessment has superseded Goldmann perimetry as the formal way of documenting visual field defects.

Basal tests

Prolactin and TSH do not have major circadian rhythms so can be checked at any time of day. Both free T4 (fT4) and TSH should be checked in pituitary disease because TSH is often normal in secondary hypothyroidism. In women, LH and FSH should be measured within the first 5 days of the menstrual cycle (follicular phase). In men, LH, FSH and basal testosterone should be checked at 09.00 in the fasting state. Basal cortisol should be checked at 09.00 to exclude deficiency, although a stimulatory (Synacthen) test is usually needed to confirm this. IGF-1 is a marker of GH activity: low or low–normal levels suggesting GH deficiency; high levels suggesting GH excess.

Dynamic pituitary tests

Dynamic endocrine tests are used to assess hormones that have a pulsatile secretion or circadian rhythm. If an endocrine deficiency is suspected, a stimulation test is used; if endocrine excess is suspected, a suppression test is used (Table 2.1). All endocrine tests should be interpreted in the clinical context.

Synacthen test

This is predominantly used to assess primary adrenal failure, but also to assess pituitary ACTH reserve. After 2 weeks of ACTH deficiency, atrophy of the adrenal cortex leads to an inadequate response to synthetic ACTH (Synacthen). This test should not be used in the acute situation, such as pituitary apoplexy, or immediately post-pituitary surgery.

Insulin tolerance test

The insulin tolerance test (ITT) is the gold standard test of ACTH and GH reserve. Insulin-induced hypoglycaemia (glucose <2.5 mmol/L) causes physiological stress, leading to a rise in ACTH and GH. A normal cortisol response to hypoglycaemia is >550 nmol/L whereas a GH value >3 µg/dL after hypoglycaemia excludes severe GH deficiency in adults. The ITT is contraindicated in patients with ischaemic heart disease and epilepsy.

Other tests of GH reserve

The ITT is the gold standard assessment of GH reserve, but is an invasive and unpleasant test to undergo. Glucagon can be used instead of the ITT, although it is a less robust test of GH reserve; nausea is a common side effect. The GHRH–arginine test has particular use in patients who have had pituitary radiotherapy. Common side effects of this are flushing, nausea and an unpleasant taste in the mouth.

Imaging

Magnetic resonance imaging (MRI) is the imaging modality of choice for the pituitary gland (Figure 2.1). Dedicated pituitary views with injection of contrast highlight the difference between tumour and normal gland. Pituitary tumours >1 cm are termed macro-adenomas, while lesions <1 cm are called micro-adenomas. Computed tomography (CT) may be adequate in patients who are unable to undergo MRI. There is increasing interest in newer imaging modalities, including 11C-methionine positron emission tomography (PET).

3Acromegaly

Acromegaly, meaning ‘large extremities’ in Greek, is almost exclusively caused by a GH-secreting pituitary tumour. Patients have often had acromegaly for many years before the diagnosis is considered. The increased detection of incidental pituitary tumours can lead to early diagnosis if appropriate tests are performed. Untreated acromegaly can lead to disfiguring features and premature death, predominantly from cardiovascular disease.

Clinical features

Acromegaly is associated with a classic constellation of clinical features (Figure 3.1). Increased size of hands and feet occur commonly, and rings may need to be cut off as they become too tight. Facial features become coarser over time, with frontal bossing of the forehead, protrusion of the chin (prognathism) and widely spaced teeth (Figure 3.2). The diagnosis is often made after the first consultation with a new healthcare professional. Soft tissue swelling leads to enlargement of the tongue and soft palate, snoring and sleep apnoea, and puffiness of the hands with carpal tunnel syndrome. Other specific features of GH hypersecretion include sweating, headaches, hypertension and diabetes mellitus, which may resolve after treatment.

Comparison with old photographs can show when acromegalic features started to develop (Figure 3.3). Patients with large pituitary tumours may present with visual field disturbance resulting from optic chiasm compression and hypopituitarism. If acromegaly occurs before puberty, gigantism occurs. Organomegaly, cardiomyopathy and increased risk of colon cancer can occur in association with acromegaly.

Investigation

Oral glucose tolerance test and IGF-1

It is relatively easy to confirm or refute a diagnosis of acromegaly once it is considered. An oral glucose tolerance test (OGTT) with 75 g glucose causes suppression of GH to <1 µg/L in patients who do not have acromegaly. Failure to suppress suggests autonomous GH secretion and a diagnosis of acromegaly. Typically, IGF-1 levels are elevated in acromegaly, reflecting increased GH activity. Some tumours co-secrete both GH and prolactin as they share the same cell origin, therefore prolactin may be simultaneously elevated.

Imaging

Pituitary MRI will reveal either a macro-adenoma or a micro-adenoma. Typically, large tumours are associated with higher GH and IGF-1 levels. Patients with cavernous sinus invasion are likely to need additional treatment because this area is relatively inaccessible surgically.

Management

Surgery is the most appropriate initial treatment for most patients as this is the only modality that offers the chance of permanent cure. With micro-adenomas, there is a high likelihood (>80%) of surgical remission, while remission is only achieved in approximately 60% of patients with macro-adenomas, hence additional treatment may be needed to achieve acceptable GH and IGF-1 levels.

Medical treatment

Somatostatin analogues (e.g. octreotide, lanreotide and pasireotide) can improve symptoms and control GH and IGF-1 levels. These drugs are usually given as monthly injections. GH receptor blockers (pegvisomant) can control IGF-1 levels in patients with aggressive acromegaly although treatment is expensive and not widely available. Dopamine agonists can control GH in certain patients with acromegaly, although less effective in patients with very high levels of GH secretion.

Radiotherapy

In patients with significant residual tumour bulk and disease activity, additional treatment may be needed. External beam or stereotactic (‘gamma knife’ or radio-surgery) radiotherapy can be used. External beam radiotherapy is more established treatment with more published outcome data, but requires daily visits to hospital for administration over several weeks. Stereotactic radiotherapy provides a more targeted treatment at higher dosage and is increasingly used, but is only suitable for lesions well away from the optic chiasm. Radiotherapy can take many years to lower GH. Long-term side effects of radiotherapy include gradual-onset hypopituitarism because of damage to the normal pituitary, and possible cerebrovascular disease.

Monitoring disease activity